cadenas

ITCC-058 ATEZOLIZUMAB

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-058 ATEZOLIZUMAB

A phase I/II, multicenter, open-label study of the safety and pharmacokinetics of anti-pd-l1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors

Promotor Name : HOFFMAN LA ROCHE

Investigator Name : B. GEOERGER

Trial registered on clinicaltrial.gov: NCT02541604